Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation.
Musto
Pellegrino
P
Carella
Angelo Michele
AM
Greco
Michele Mario
MM
Falcone
Antonietta
A
Sanpaolo
Grazia
G
Bodenizza
Carlo
C
Cascavilla
Nicola
N
Melillo
Lorella
L
Carella
Angelo Michele
AM
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation; D000069283:Rituximab; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab